Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS) -- Ignore unavailable to you. Want to Upgrade?

To: celeryroot.com who wrote (3209)	8/19/1998 3:46:00 PM
From: Graham Marshman	Read Replies (1) \| Respond to of 4028

Clinical status is determined on a drug by drug basis. In a preclinical stage the company is proving that it works. Once they've finished testing a specific item, it's not in a preclinical stage any more. It could be useless - research to be discontinued. It could be a potential for an IND, which may not actually happen due to various reasons eg available cash, company strategic decisions etc. It may have an IND generated and be rejected. All these cases are neither in preclinical or clinical stages. Clinical trial status is only gained by an approved IND. That's my understanding. re FDA, you might be right - I don't know. Graham